Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

To determine the clinical and biologic effects of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status of 0 to 2, and compensated liver...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 26; číslo 18; s. 2992
Hlavní autoři:	Siegel, Abby B, Cohen, Emil I, Ocean, Allyson, Lehrer, Deborah, Goldenberg, Alec, Knox, Jennifer J, Chen, Helen, Clark-Garvey, Sean, Weinberg, Alan, Mandeli, John, Christos, Paul, Mazumdar, Madhu, Popa, Elizabeta, Brown, Jr, Robert S, Rafii, Shahin, Schwartz, Jonathan D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 20.06.2008
Témata:	Adult Aged Aged, 80 and over Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Animals Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - blood supply Carcinoma, Hepatocellular - drug therapy Chemokine CXCL12 - blood Disease-Free Survival Humans Infusions, Intravenous Liver Neoplasms - blood Liver Neoplasms - blood supply Liver Neoplasms - drug therapy Magnetic Resonance Angiography - methods Male Middle Aged Neovascularization, Pathologic - blood Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Vascular Endothelial Growth Factor A - blood
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!